secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001104659-26-018312
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio appoints Eisner and Nirula to board; Graham resigns
------------------------------------------------------------

- Neil Graham resigned from Zura's board effective Feb 21, 2026; departure not due to any disagreement.
- Mark Eisner (Vir Bio CMO) and Ajay Nirula (Recludix Pharma EVP R&D, former Lilly exec) appointed as directors.
- Each new director receives $40k annual cash retainer and initial option for up to 51,000 shares (or $200k value).
- Board changes come as Zura advances Phase 2 tibulizumab trials in hidradenitis suppurativa and systemic sclerosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926018312/0001104659-26-018312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926018312/tm267035d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer